Relief as treatment for rare condition is extended
NHS access to the drug Brineura, which slows the progress of Batten disease, was set to end this month but NICE and NHS England have now come to new agreement with the drug's maker.
One of those who receives it is Isaac, eight, who has CLN2 Batten disease, which was diagnosed in August 2021.
His mother Aimee Tilley, from Kettering in Northamptonshire, said: "We know it's not a cure, we still see regression, but it's a huge amount slower, so he's gaining years, not just days or weeks."
Batten disease, a rare genetic disorder, causes a rapid decline in a child's ability to walk, talk and see, and is estimated to affect about 40 children in the UK - with an average life expectancy of about 10 years.
Brineura is the only approved treatment that slows the condition's progress.
The new agreement will mean those on the drug, and those who start the treatment before the end of the year, can receive it on a permanent basis.
Ms Tilley said: "We are extremely relieved that Isaac is going to continue to have this treatment.
"This black cloud that we've had hanging over us has gone. We feel like we can live again."
NICE said it and NHS England would continue to work with BioMarin, which makes the drug, on "a solution to secure access to all future patients but at the moment the treatment is not considered cost effective".
Ms Tilley says her family "will not stop fighting for the children of the future".
She said: "They deserve it just as much as the children now and we have won this battle, but we will win the war."
Ms Tilley said Isaac was "having seizures, losing his mobility, he can still walk with a walker or walk holding our hands [and] he has now gone blind".
But, she added: "He's happy. He still enjoys theme parks, going horse riding and he still does a lot of things that children of his age can do we just have to adapt them for him."
Helen Knight, director of medicines evaluation at NICE, said she was "pleased" an agreement had been reached.
She added that NICE and NHS England remained "committed to working with the company to try to reach a long-term deal that will give access to [Brineura] to all eligible people" after December.
Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
Threat to son's treatment for rare disease 'agony'
Mothers rally and urge action over access to drug
NICE
NHS England
Batten Disease Family Association (BDFA)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
- All eligible people with CF in England can now benefit from this medicine - LONDON, July 14, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine. This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. "We're proud that ALYFTREK®, our fifth CF medicine, is available today as another treatment option for all eligible CF patients in England. It represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease," said Ludovic Fenaux, Senior Vice President, Vertex International. "In our pivotal studies, ALYFTREK® demonstrated the potential for even better outcomes for patients than KAFTRIO® (ivacaftor/tezacaftor/elexacaftor). We're pleased to have reached this agreement with NHS England that recognises the value that this new medicine brings to CF patients, their families and society." Following the European regulatory approval, eligible patients in Ireland, Denmark and Germany will be the first ones to access deutivacaftor/tezacaftor/vanzacaftor in the European Union. Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands, and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents approximately 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. About ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements made by Ludovic Fenaux in this press release and statements regarding the expectations for the potential benefits of ALYFTREK, expectations for patient access to deutivacaftor/tezacaftor/vanzacaftor, and Vertex's continued work with reimbursement bodies across the EU member states to ensure access for all eligible patients as quickly as possible. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at and You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. View source version on Contacts Media: mediainfo@ orU.S.: 617-341-6992orInternational: +44 20 3204 5275 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Less aggressive treatment for low-risk breast cancer ‘just as effective'
More targeted and less aggressive radiotherapy for low-risk breast cancer could spare thousands of women from the harsh side-effects of the treatment, a trial has found. The technique, which has since been adopted by the NHS, has 'transformed' the way the disease is treated in its early stages, researchers said. More than 37,000 women have radiotherapy for breast cancer in the UK every year. The treatment uses radiation to kill cancer cells and is usually given after surgery to reduce the risk of the disease coming back. However, side-effects can include changes in breast size and shape, swelling in the arms or breast, and pain. The Import Low trial, led by The Institute of Cancer Research, London, and the University of Cambridge, found limiting radiation to the tumour area, rather than treating the whole breast, was just as effective. The study included 2,018 women across 30 radiotherapy centres in the UK, who were monitored for 10 years after treatment. It compared three radiotherapy approaches; whole-breast, partial-breast and a reduced-dose. After a decade, cancer recurrence rates in the group given partial radiotherapy was 3%, the same proportion as those who had been treated with a more aggressive approach. Patients who had targeted radiotherapy were also less likely to experience long-term changes in breast appearance. Some 15% reported noticeable changes at five years compared with 27% in the whole-breast radiotherapy group. Dr Anna Kirby, consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, and reader in breast cancer radiotherapy at The Institute of Cancer Research, London, said: 'The long-term results of this study confirm that a less aggressive approach, limiting radiotherapy to the tumour rather than the whole breast, is just as effective as traditional whole-breast radiotherapy. 'Patients receiving partial-breast radiotherapy experience fewer side-effects while maintaining excellent cancer control.' Charlotte Coles, a professor of breast cancer clinical oncology at the University of Cambridge, honorary clinical oncology consultant at Cambridge University Hospitals NHS Foundation Trust, and chief investigator of the Import Low study, said the trial has 'transformed' how early breast cancer is treated. Following the study, which is published in the Lancet Oncology, partial-breast radiotherapy has been integrated into NHS treatment guidelines. It is hoped that more than 9,000 women in the UK could benefit from more targeted treatment. 'By targeting the area around the tumour, rather than the whole breast, we have demonstrated that patients can achieve the same outstanding long-term outcomes with fewer complications,' Prof Coles said. 'This approach is now widely adopted across the NHS, sparing thousands of women from unnecessary radiation exposure. 'The results of this study have not only shaped UK clinical practice but also informed international guidelines, ensuring that women worldwide benefit from this personalised, evidence-based treatment.' Hilary Stobart, now 70, was diagnosed with ER-positive breast cancer in December 2008, with a 2cm tumour in her left breast. Ms Stobart, who was 54 at the time, was offered the chance to take part in the trial after surgery and was treated with partial radiotherapy. 'I had three weeks of radiotherapy, but suffered no side-effects, other than some soreness in my breast and nipple in the first few weeks,' she said. 'Ten years on, I am doing fine. I have no side-effects and no recurrence of disease. 'For me personally, I am very thankful to have received the lowest dose of radiotherapy. 'Whilst I may have had some niggling worries in the early days, having seen the results of the trial, I feel positive and optimistic now. I know that I was lucky enough back then to have had the best treatment, a treatment that other women will be routinely offered now.' Dr Fay Cafferty, lead statistician at The Institute of Cancer Research, London, added that the findings are 'crucial in reinforcing the long-term safety and effectiveness of partial-breast radiotherapy'. 'Long-term data is vital to ensure we know there's no greater risk of breast cancer returning after this targeted radiotherapy treatment,' she said. 'This latest analysis confirms that partial breast radiotherapy remains a safe and effective treatment option, supporting its continued adoption as the standard of care in the UK and globally.'
Business Wire
2 hours ago
- Business Wire
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK ® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis (CF) medicine ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine. This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 'We're proud that ALYFTREK ®, our fifth CF medicine, is available today as another treatment option for all eligible CF patients in England. It represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease,' said Ludovic Fenaux, Senior Vice President, Vertex International. 'In our pivotal studies, ALYFTREK ® demonstrated the potential for even better outcomes for patients than KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor). We're pleased to have reached this agreement with NHS England that recognises the value that this new medicine brings to CF patients, their families and society.' Following the European regulatory approval, eligible patients in Ireland, Denmark and Germany will be the first ones to access deutivacaftor/tezacaftor/vanzacaftor in the European Union. Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands, and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents approximately 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. About ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements made by Ludovic Fenaux in this press release and statements regarding the expectations for the potential benefits of ALYFTREK, expectations for patient access to deutivacaftor/tezacaftor/vanzacaftor, and Vertex's continued work with reimbursement bodies across the EU member states to ensure access for all eligible patients as quickly as possible. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at and You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
